A double-blind, randomized, placebo-controlled study of the efficacy, safety/tolerability, and pharmacokinetic profile of UCB0942 in adult patients with highly drug-resistant focal epilepsy
Phase of Trial: Phase II
Latest Information Update: 23 Aug 2017
At a glance
- Drugs Padsevonil (Primary)
- Indications Partial epilepsies
- Focus Therapeutic Use
- Sponsors UCB
- 16 Aug 2017 Status changed from active, no longer recruiting to completed.
- 16 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017.
- 04 Nov 2016 Planned End Date changed from 1 Oct 2016 to 1 Dec 2016.